Acumen Pharmaceuticals is engaged in the discovery and development of targeted therapies for the treatment of Alzheimer's disease ("AD"). Co.'s lead drug candidate, ACU193 is a humanized monoclonal antibody that selectively targets amyloid-beta oligomers, has demonstrated functional and protective effects in in vitro assays, and has demonstrated in vivo safety and pharmacologic activity in multiple animal species, including transgenic models for ADs. Co. and Merck & Co. discovered and developed ACU193 through an eight-year research collaboration. Co. holds exclusive rights to the program. Co. submitted an Investigation Drug Application for ACU193 to the Food and Drug Administration. We show 3 historical shares outstanding datapoints in our coverage of ABOS's shares outstanding history.
Understanding the changing numbers of ABOS shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ABOS versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ABOS by allowing them to research ABOS shares outstanding history
as well as any other stock in our coverage universe. |
Free ABOS Email Alerts:
Video: Shares Outstanding Importance
